文献速递垂体与肾上腺疾病

英国13家垂体中心多中心研究:Nelson综合征初次治疗后的结局

Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该回顾性队列研究纳入英国13家垂体中心的68例Nelson综合征患者,中位影像随访13年。结果显示10年肿瘤无进展生存率为62%,CD诊断前接受手术+放疗+肾上腺切除术者进展风险最高(HR 4.6)。

要点

  • Nelson综合征10年肿瘤进展率为38%。
  • CD诊断前治疗复杂者肿瘤进展风险更高。
  • 不同NS一线管理方式间进展风险无显著差异。

核心结论

  • 随访10年时,38%的Nelson综合征患者出现促肾上腺皮质激素肿瘤进展。
  • Nelson综合征诊断前库欣病治疗的复杂性可预测长期肿瘤预后。
  • CD诊断前接受手术+放疗+肾上腺切除术者肿瘤进展风险最高(HR 4.6;95%CI 1.6-13.5)。

研究设计与样本

  • 回顾性队列研究,纳入英国13家垂体中心的68例Nelson综合征患者。
  • 自Nelson综合征诊断起中位影像随访13年(范围1-45年)。

主要发现

  • 10年肿瘤无进展生存率为62%(手术80%,放疗52%,手术+放疗81%,观察51%)。
  • 性别、CD或NS诊断时年龄、CD诊断时腺瘤大小、肾上腺切除术前影像有无垂体瘤、NS主要管理方式均非肿瘤进展的预测因素。
  • 随访期间3%患者发生恶性转化伴脊柱转移,4%死于肿瘤侵袭性增大。

关键数值与推荐

  • CD诊断前治疗方式:手术+肾上腺切除术30例(其中8例接受2次、1例接受3次垂体手术),手术+放疗+肾上腺切除术17例,放疗+肾上腺切除术2例,肾上腺切除术19例。
  • NS主要管理包括手术、放疗、手术+放疗和观察。
  • CD诊断前治疗方式为肿瘤进展的显著预测因素,手术+放疗+肾上腺切除术组风险最高(HR 4.6;95%CI 1.6-13.5)。

临床怎么用

  • 对Nelson综合征患者应长期影像随访以监测肿瘤进展。
  • 需关注库欣病诊断前治疗复杂(尤其手术+放疗+肾上腺切除术)患者的更高进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Long-term outcomes of patients with Nelson's syndrome (NS) have been poorly explored, especially in the modern era. OBJECTIVE: To elucidate tumor control rates, effectiveness of various treatments, and markers of prognostic relevance in patients with NS. PATIENTS, DESIGN, AND SETTING: Retrospective cohort study of 68 patients from 13 UK pituitary centers with median imaging follow-up of 13 years (range 1-45) since NS diagnosis. RESULTS: Management of Cushing's disease (CD) prior to NS diagnosis included surgery+adrenalectomy (n = 30; eight patients had 2 and one had 3 pituitary operations), surgery+radiotherapy+adrenalectomy (n = 17; two received >1 courses of irradiation, two had ≥2 pituitary surgeries), radiotherapy+adrenalectomy (n = 2), and adrenalectomy (n = 19). Primary management of NS mainly included surgery, radiotherapy, surgery+radiotherapy, and observation; 10-year tumor progression-free survival was 62% (surgery 80%, radiotherapy 52%, surgery+radiotherapy 81%, observation 51%). Sex, age at CD or NS diagnosis, size of adenoma (micro-/macroadenoma) at CD diagnosis, presence of pituitary tumor on imaging prior adrenalectomy, and mode of NS primary management were not predictors of tumor progression. Mode of management of CD before NS diagnosis was a significant factor predicting progression, with the group treated by surgery+radiotherapy+adrenalectomy for their CD showing the highest risk (hazard ratio 4.6; 95% confidence interval, 1.6-13.5). During follow-up, 3% of patients had malignant transformation with spinal metastases and 4% died of aggressively enlarging tumor. CONCLUSIONS: At 10 years follow-up, 38% of the patients diagnosed with NS showed progression of their corticotroph tumor. Complexity of treatments for the CD prior to NS diagnosis, possibly reflecting corticotroph adenoma aggressiveness, predicts long-term tumor prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fountas A, Lim ES, Drake WM, et al. Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. J Clin Endocrinol Metab. 2020. PMID: 31735971. doi:10.1210/clinem/dgz200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。